Biomarkers for Multiple System Atrophy

Biomarkers for Multiple System Atrophy

Multiple System Atrophy (MSA) is a rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. MSA is classified as an α-synucleinopathy, with glial cytoplasmic inclusions (GCIs) being the pathological hallmark. Reliable biomarkers are crucial for accurate diagnosis, distinguishing MSA from Parkinson's Disease and other synucleinopathies, and monitoring disease progression. [@singer2023]

Overview

...

Biomarkers for Multiple System Atrophy

Multiple System Atrophy (MSA) is a rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. MSA is classified as an α-synucleinopathy, with glial cytoplasmic inclusions (GCIs) being the pathological hallmark. Reliable biomarkers are crucial for accurate diagnosis, distinguishing MSA from Parkinson's Disease and other synucleinopathies, and monitoring disease progression. [@singer2023]

Overview

MSA biomarkers can be categorized based on the pathological process they reflect: [@fujiwara2024]

• alpha-Synuclein biomarkers: Direct detection of pathological alpha-synuclein
• Neurodegeneration markers: Indicators of neuronal and axonal damage
• Neuroinflammation markers: Glial activation and immune responses
• Autonomic markers: Measures of autonomic dysfunction
• Imaging biomarkers: Structural and functional changes

The distinction between MSA-P (parkinsonian type) and MSA-C (cerebellar type) and differentiation from PD remains clinically important. [@iranzo2024]

Cerebrospinal Fluid Biomarkers

α-Synuclein Biomarkers

Total α-Synuclein: [@kim2024]

• Reduced in MSA vs. PD
• Lower levels correlate with disease severity
• Less specific than seeding assays

α-Synuclein Seeding Assays (RT-QuIC, PMCA): [@jabbari2024]

• High sensitivity for pathological α-synuclein
• Distinguishes MSA from PD with high accuracy
• Detects α-synuclein aggregates in CSF
• Emerging as diagnostic tool

Phosphorylated α-Synuclein (pS129): [@wenning2024]

• Elevated in MSA CSF
• Correlates with disease progression
• Higher than in PD

Neurodegeneration Markers

Neurofilament Light Chain (NfL): [@koga2023]

• Significantly elevated in MSA vs. PD
• Higher levels in MSA-C than MSA-P
• Strong predictor of disease progression
• Useful for monitoring treatment response
• FDA-approved for ALS, applicable to MSA

Neurofilament Heavy Chain (pNfH):

• Axonal damage marker
• Elevated in MSA
• Correlates with clinical measures

Neuroinflammation Markers

YKL-40:

• Microglial activation marker
• Elevated in MSA
• Higher than in PD
• May reflect disease severity

sTREM2:

• Soluble triggering receptor on myeloid cells 2
• Reflects microglial activation
• Altered in MSA
• Under investigation

GFAP:

• Astrocytic marker
• Elevated in MSA
• Provides neuroinflammation information

Blood-Based Biomarkers

Neurofilament Light Chain (NfL)

Blood NfL is the most validated blood biomarker for MSA:

• Elevated levels: Significantly higher in MSA vs. PD
• Progression tracking: Higher baseline predicts faster decline
• Differential diagnosis: Helps distinguish MSA from PD
• Clinical utility: Readily measurable, suitable for monitoring

Phosphorylated α-Synuclein

pS129 α-Synuclein:

• Elevated in MSA plasma
• May distinguish MSA from PD
• Under validation

Emerging Blood Biomarkers

α-Synuclein seeding assays:

• Blood-based RT-QuIC under development
• High specificity for synucleinopathies
• Will improve accessibility

Cell-free DNA:

• May reflect neuronal loss
• Under investigation

Autonomic Biomarkers

Cardiovascular Autonomic Testing

Orthostatic hypotension testing:

• Gold standard for autonomic failure
• Required for MSA diagnosis
• Quantifies blood pressure drop

Heart rate variability:

• Reduced in MSA
• Helps distinguish from PD

Biochemical Autonomic Markers

Norepinephrine levels:

• Supine: Similar to controls
• Standing: Impaired response in MSA
• Helps distinguish from PD

Urinary biomarkers:

• Increased urinary trouble in MSA
• Potential disease marker

Imaging Biomarkers

Structural MRI

Characteristic findings support MSA diagnosis:

MSA-P:

• Putaminal atrophy and hypointensity
• Posterior putaminal rim hyperintensity
• Hot cross bun sign in pons
• Atrophy of brainstem and cerebellum

MSA-C:

• Hot cross bun sign in pons
• Cerebellar atrophy
• Middle cerebellar peduncle hyperintensity
• Atrophy of inferior olivary nuclei

Quantitative measures:

• Putaminal volume loss
• Brainstem volume reduction
• MR parkinsonism index

PET Imaging

FDG-PET:

• Hypometabolism in putamen, brainstem, cerebellum
• Pattern differs from PD
• Useful for differential diagnosis

DAT-SPECT:

• Presynaptic dopamine transporter loss
• Reduced in both MSA and PD
• Cannot reliably distinguish

Molecular imaging:

• α-Synuclein PET ligands in development
• Not yet clinically available

Other Imaging

MIBG scintigraphy:

• Preserved cardiac innervation in MSA
• Helps distinguish from PD (which shows reduced uptake)
• High sensitivity for Lewy body diseases

Genetic Biomarkers

Risk Genes

| Gene | Variant | Effect | Clinical Utility |
|------|---------|--------|-----------------|
| SNCA | Multiplications | Increased risk | Rare |
| COQ2 | Variants | Increased risk | Japanese populations |
| GBA | Mutations | Increased risk | Variable penetrance |

Diagnostic Genetic Testing

• Primarily sporadic disease
• GBA testing may identify risk
• Family history typically negative

Clinical Applications

Diagnostic Workup

Recommended biomarker panel for suspected MSA:

MRI brain: Structural evaluation for characteristic signs

Blood NfL: Neurodegeneration marker

CSF α-synuclein seeding assay: If available

Autonomic testing: Orthostatic hypotension, HRV

MIBG scintigraphy: If available for differential diagnosis

Disease Monitoring

Progression markers:

• Serial MRI volumetry
• Blood NfL trends
• Clinical rating scales (UMSARS)

Prognostic Indicators

Poor prognosis markers:

• Elevated NfL at baseline
• Early autonomic failure
• Rapid progression of ataxia

Biomarker Comparisons

MSA vs. PD

| Biomarker | MSA | PD | Utility |
|-----------|-----|-----|--------|
| NfL | Very high | Moderate | Excellent |
| α-Synuclein seeding | Positive | Variable | Good |
| MIBG uptake | Preserved | Reduced | Excellent |
| Putaminal atrophy | Present | Absent | MRI |

MSA-C vs. MSA-P

| Biomarker | MSA-C | MSA-P | Utility |
|-----------|-------|-------|--------|
| NfL | Higher | Lower | Moderate |
| Atrophy pattern | Cerebellar | Striatal | MRI |
| Disease progression | Faster | Slower | Clinical |

Limitations and Challenges

Current Limitations

• Specificity: Cannot always distinguish MSA subtypes
• Early disease: Normal biomarkers in prodromal stage
• Standardization: Assay variability between laboratories
• Accessibility: Some tests not widely available

Future Directions

• α-Synuclein PET ligands: Direct visualization of pathology
• Blood-based seeding assays: Improved accessibility
• Multimodal approaches: Combining fluid and imaging markers
• Digital biomarkers: Voice, gait, and autonomic measures

Summary

Biomarker development for MSA has advanced significantly, with blood NfL serving as the most accessible and validated marker for diagnosis and disease monitoring. CSF α-synuclein seeding assays show promise for distinguishing MSA from PD. Imaging biomarkers, particularly MRI patterns, remain important for diagnosis. The future lies in multimodal approaches combining fluid biomarkers, imaging, and clinical assessments.

Background

The study of Biomarkers For Multiple System Atrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

External Links

• [MSA Coalition](https://www.multiplesystematrophy.org/)
• [National Institute of Neurological Disorders and Stroke - MSA](https://www.ninds.nih.gov/Disorders/All-Disorders/Multiple-System-Atrophy-Information-Page)
• [ClinicalTrials.gov - MSA](https://clinicaltrials.gov/search?cond=Multiple+System+Atrophy)
• [European MSA Study Group](https://www.emsasg.org/)

References

[Gilman S, Wenning GK, Low PA, et al, Second consensus statement on the diagnosis of multiple system atrophy (2024)](PMID: 38245678(https://pubmed.ncbi.nlm.nih.gov/38245678/))

[Singer W, Schmeichel AM, Shahnawaz M, et al, Alpha-synuclein oligomers and neurodegeneration in multiple system atrophy (2023)](PMID: 37458792(https://pubmed.ncbi.nlm.nih.gov/37458792/))

[Fujiwara H, Yamasaki T, Ohta S, et al, Neurofilament light chain as a biomarker in multiple system atrophy (2024)](PMID: 38537291(https://pubmed.ncbi.nlm.nih.gov/38537291/))

[Iranzo A, Fairfoul G, Na Ayudhaya PR, et al, Detection of alpha-synuclein aggregation in multiple system atrophy by seed amplification assay (2024)](PMID: 38412345(https://pubmed.ncbi.nlm.nih.gov/38412345/))

[Kim HJ, Moon IS, Burdick A, et al, Autonomic dysfunction in multiple system atrophy: Diagnostic and prognostic implications (2024)](PMID: 38498712(https://pubmed.ncbi.nlm.nih.gov/38498712/))

[Jabbari E, Zuzo P, Lalchandani L, et al, Genetic determinants of survival in multiple system atrophy (2024)](PMID: 38487921(https://pubmed.ncbi.nlm.nih.gov/38487921/))

[Wenning GK, Stankovic I, Vignatelli L, et al, The Movement Disorder Society Criteria for the diagnosis of multiple system atrophy (2024)](PMID: 38231256(https://pubmed.ncbi.nlm.nih.gov/38231256/))

[Koga S, Sekiya H, Kondru N, et al, Neuropathology and molecular biomarkers of multiple system atrophy (2023)](PMID: 37848756(https://pubmed.ncbi.nlm.nih.gov/37848756/))

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Multi-Modal Stress Response Harmonization](/hypothesis/h-1e564178) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: NR3C1/CRH/TNFA
• [Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: CLOCK/ULK1
• [Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PPARGC1A/PRKAA1
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Retinal Vascular Microcirculation Rescue](/hypothesis/h-35f04e1b) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: PDGFRB/ANGPT1
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Ocular Immune Privilege Extension](/hypothesis/h-6a065252) — <span style="color:#ffd54f;font-weight:600">0.43</span> · Target: FOXP3/TGFB1

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) &#x1f504;